Physicians compliance during maintenance therapy in children with Down syndrome and acute lymphoblastic leukemia

Leukemia

Volumn 27, Issue 4, 2013, Pages 866-870

  Bohnstedt, C ^a   Levinsen, M ^a   Rosthoj S ^b   Zeller, B ^c   Taskinen, M ^d   Hafsteinsdottir, S ^e   Bjorgvinsdottir H ^f   Heyman, M ^f   Schmiegelow, K ^a,g  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^e LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^f KAROLINSKA INSTITUTE   (Sweden)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

acute lymphoblastic leukemia; compliance; dose intensity; Down syndrome; maintenance therapy; methotrexate 6 mercaptopurine

Indexed keywords

DOXORUBICIN; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; DOWN SYNDROME; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; GENDER; HUMAN; INFANT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD;

CHILD; CHILD, PRESCHOOL; DOWN SYNDROME; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84876159587     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.325     Document Type: Review

References (43)

1. Hasle H. Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol 2001; 2: 429-436.
2. Roizen NJ, Amarose AP. Hematologic abnormalities in children with Down syndrome. Am J Med Genet 1993; 46: 510-512.
3. Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol 2000; 110: 512-524.
4. Malinge S, Izraeli S, Crispino JD. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood 2009; 113: 2619-2628.
5. Zeller B, Gustafsson G, Forestier E, Abrahamsson J, Clausen N, Heldrup J et al. Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol 2005; 128: 797-804.
6. Bassal M, La MK, Whitlock JA, Sather HN, Heerema NA, Gaynon PS et al. Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer 2005; 44: 21-28.
7. Chessells JM, Harrison G, Richards SM, Bailey CC, Hill FG, Gibson BE et al. Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Arch Dis Child 2001; 85: 321-325.
8. Levitt GA, Stiller CA, Chessells JM. Prognosis of Down's syndrome with acute leukaemia. Arch Dis Child 1990; 65: 212-216.
9. Maloney KW, Carroll WL, Carroll AJ, Devidas M, Borowitz MJ, Martin PL et al. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. Blood 2010; 116: 1045-1050.
10. Rabin KR, Whitlock JA. Malignancy in children with trisomy 21. Oncologist 2009; 14: 164-173.
11. Shah N, Al-Ahmari A, Al-Yamani A, Dupuis L, Stephens D, Hitzler J. Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with Down syndrome. Pediatr Blood Cancer 2009; 52: 14-19.
12. Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells RJ, Trigg M et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2005; 106: 4043-4049.
13. Zwaan CM, Reinhardt D, Hitzler J, Vyas P. Acute leukemias in children with Down syndrome. Hematol Oncol Clin N Am 2010; 24: 19-34.
14. Forestier E, Izraeli S, Beverloo B, Haas O, Pession A, Michalova K et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood 2008; 111: 1575-1583.
15. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000; 355: 165-169.
16. Taub JW, Ge Y. Down syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer 2005; 44: 33-39.
17. Forestier E, Schmiegelow K. The incidence peaks of the childhood acute leukemias reflect specific cytogenetic aberrations. J Pediatr Hematol Oncol 2006; 28: 486-495.
18. Blink M, Buitenkamp TD, van den Heuvel-Eibrink MM, Danen-van Oorschot AA, de HV, Reinhardt D et al. Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. Leukemia 2011; 25: 1365-1368.
19. Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 2010; 115: 1006-1017.
20. Buitenkamp TD, Mathot RA, de HV, Pieters R, Zwaan CM. Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia. Haematologica 2010; 95: 1106-1113.
21. Schmiegelow K, Bjork O, Glomstein A, Gustafsson G, Keiding N, Kristinsson J et al. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J Clin Oncol 2003; 21: 1332-1339.
22. Bohnstedt C, Taskinen M, Zeller B, Bjorgvinsdottir H, Hafsteinsdottir S, Schmiegelow K. Poor treatment compliance in children with Down syndrome and acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2009; 31: 79-80.
23. Gustafsson G, Schmiegelow K, Forestier E, Clausen N, Glomstein A, Jonmundsson G et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 2000; 14: 2267-2275.
24. Schmiegelow K, Forestier E, Hellebostad M, Heyman M, Kristinsson J, Soderhall S et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 345-354.
25. Martinussen TASTH. Dynamic Regression Models for Survival Data. Springer: Berlin, 2006.
26. Lin DY, Wei LJ, Ying Z. Model-checking techniques based on cumulative residuals. Biometrics 2002; 58: 1-12.
27. Schmiegelow K, Heyman M, Kristinsson J, Mogensen UB, Rosthoj S, Vettenranta K et al. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. J Pediatr Hematol Oncol 2009; 31: 385-392.
28. Davidsen ML, Dalhoff K, Schmiegelow K. Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2008; 30: 831-849.
29. Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol 2009; 146: 489-503.
30. Arico M, Baruchel A, Bertrand Y, Biondi A, Conter V, Eden T et al. The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29-30, 2005. Leukemia 2005; 19: 1145-1152.
31. Schmiegelow K, Pulczynska MK. White-cell counts in childhood acute lymphoblastic leukemia. Eur J Haematol 1990; 44: 72-74.
32. Schmiegelow K, Ifversen M. Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 1996; 13: 433-441.
33. Prasher VP. Screening of medical problems in adults with Down syndrome. Down Syndrome Res Pract 1994; 2: 59-66.
34. David O, Fiorucci GC, Tosi MT, Altare F, Valori A, Saracco P et al. Hematological studies in children with Down syndrome. Pediatr Hematol Oncol 1996; 13: 271-275.
35. Skarby TV, Anderson H, Heldrup J, Kanerva JA, Seidel H, Schmiegelow K. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia. Leukemia 2006; 20: 1955-1962.
36. Peeters MA, Megarbane A, Cattaneo F, Rethore MO, Lejeune J. Differences in purine metabolism in patients with Down's syndrome. J Intellect Disabil Res 1993; 37(Part 6): 491-505.
37. Peeters MA, Lejeune J. Beneficial effect of 6-mercaptopurine on the mitotic index of trisomy 21 lymphocytes. Implications for future research. Ann Genet 1989; 32: 21-25.
38. Brodsky G, Barnes T, Bleskan J, Becker L, Cox M, Patterson D. The human GARSAIRS-GART gene encodes two proteins which are differentially expressed during human brain development and temporally overexpressed in cerebellum of individuals with Down syndrome. Hum Mol Genet 1997; 6: 2043-2050.
39. Hedeland RL, Hvidt K, Nersting J, Rosthoj S, Dalhoff K, Lausen B et al. DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma. Cancer Chemother Pharmacol 2010; 66: 485-491.
40. Caver TE, Slobod KS, Flynn PM, Behm FG, Hudson MM, Turner EV et al. Profound abnormality of the B/T lymphocyte ratio during chemotherapy for pediatric acute lymphoblastic leukemia. Leukemia 1998; 12: 619-622.
41. Nygaard U, Toft N, Schmiegelow K. Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clin Pharmacol Ther 2004; 75: 274-281.
42. Schmiegelow M, Hertz H, Schmiegelow K, Holm K, Muller J. Insulin-like growth factor-I and insulin-like growth factor binding protein-3 during maintenance chemotherapy of acute lymphoblastic leukemia in children. J Pediatr Hematol Oncol 1999; 21: 268-273.
43. Gregory L, Williams R, Thompson E. Leucocyte function in Down's syndrome and acute leukaemia. Lancet 1972; 1: 1359-1361.